Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 tivantinib versus placebo in MET-high inoperable hepatocellular carcinoma after prior sorafenib
2012-003308-10Phase 3Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tivantinib in hepatocellular carcinoma (HCC), sponsored by Daiichi Sankyo Co., Ltd.. Started Dec 2012; status: terminated.
02
Drugs
tivantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2012-003308-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003308-10.